Retrospective Real-Life Data, Efficacy and Safety of Vismodegib Treatment in Patients with Advanced and Multiple Basal Cell Carcinoma: 3-Year Experience from a Spanish Center

Angela Ayén-Rodríguez (), Laura Linares-González, Carlos Llamas-Segura, Francisco Manuel Almazán-Fernández and Ricardo Ruiz-Villaverde
Additional contact information
Angela Ayén-Rodríguez: Dermatology Department, Hospital Universitario San Cecilio, 18016 Granada, Spain
Laura Linares-González: Dermatology Department, Hospital Universitario San Cecilio, 18016 Granada, Spain
Carlos Llamas-Segura: Dermatology Department, Hospital Universitario San Cecilio, 18016 Granada, Spain
Francisco Manuel Almazán-Fernández: Dermatology Department, Hospital Universitario San Cecilio, 18016 Granada, Spain
Ricardo Ruiz-Villaverde: Dermatology Department, Hospital Universitario San Cecilio, 18016 Granada, Spain

IJERPH, 2023, vol. 20, issue 10, 1-10

Abstract: Background: Basal cell carcinoma (BCC) is the most common type of skin cancer and can represent a therapeutic challenge in patients with locally advanced disease. Vismodegib is a hedgehog pathway inhibitor approved by the FDA for use in this type of tumor. We present a case series to describe our experience with the use of vismodegib. Methods: A retrospective study that included patients treated with vismodegib at our dermatology unit was conducted. Monthly follow-up was performed, and we registered the clinical evolution and adverse reactions. Results: A total of six patients with locally advanced BCCs were included (50% males and 50% females), with a mean age of 78.5 years old. The treatment was administered over a mean of 5 months. A complete response was observed in four cases and partial response in two cases. No recurrence was detected, with a median follow-up duration after discontinuation of 18 months. Most patients (83%) had at least one adverse event, and two needed dose adjustment temporarily or permanently to continue. The main adverse effect was muscle spasms (66.7%). The main limitation of our study was the small sample, which was not representative of the general population. Conclusions: Vismodegib is a safe and effective treatment for locally advanced BCC, and its role in unresectable BCC seems to be an important option in these challenging cases.

Keywords: nonmelanoma skin cancer; locally advanced basal cell carcinoma; hedgehog inhibitor; vismodegib (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2023
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/20/10/5824/pdf (application/pdf)
https://www.mdpi.com/1660-4601/20/10/5824/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:20:y:2023:i:10:p:5824-:d:1147119

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().